

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-24) BIMEKIZUMAB
 PRONUNCIATION bye" me kiz' ue mab
 THERAPEUTIC CLAIM Treatment of moderate to severe plaque psoriasis

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human interleukin 17A/interleukin 17F)(human-*Rattus norvegicus* monoclonal UCB4940 heavy chain), disulfide with human-*Rattus norvegicus* monoclonal UCB4940 light chain, dimer
2. Immunoglobulin G1-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A) and *Homo sapiens* IL17F (interleukin 17F)], humanized monoclonal antibody; gamma1 heavy chain (1-455) [humanized VH (*Homo sapiens* IGHV3-7*01 (88.70%) -(IGHD)-IGHJ1*01) [8.8.18] (1-125)-*Homo sapiens* IGHG1*01 (CH1 (126-223), hinge (224-238), CH2 (239- 348), CH3 (349-453), CHS (454-455)) (126-455)], (228-214')- disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-13*02 (80.00%) -IGKJ1*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01 (108'-214')]; dimer (234-234":237-237")- bisdisulfide

STRUCTURAL FORMULA

Heavy chain

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	DYNMAWVRQA	PGKGLEWVAT	50
ITYEGRNTYY	RDSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCASPP	100
QYYEGSIYRL	WFAHWGQGTL	VTVSSASTKG	PSVFPPLAPSS	KSTSGGTAAL	150
GCLVKDYFPE	PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVVTVPSSS	200
LGTQTYICNV	NHKPSNTKVD	KKVEPKSCDK	THTCPPCPAP	ELLGGPSVFL	250
FPPKPKDTLM	ISRTPETVTCV	VVDVSHEDPE	VKFNWYVDGV	EVHNAKTKPR	300
EEQYNSTYRV	VSVLTVLHQD	WLNGKEYKCK	VSNKALPAPI	EKTISKAKGQ	350
PREPQVYTLF	PSRDELTKNQ	VSLTCLVKGF	YPSDIAVEWE	SNGQPENNYK	400
TTPPVLDSDG	SFFFLYSKLTV	DKSRWQQGNV	FSCSVMHEAL	HNHYTQKSLS	450
LSPGK					455

Light chain

AIQLTQSPSS	LSASVGDVRT	ITCRADESVR	TLMHWYQQKP	GKAPKLLIYL	50'
VSNSEIGVPD	RFSGSGSGTD	FRLTISSLQP	EDFATYYCQQ	TWSDPWTFGQ	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges

22-96	22''-96''	23'-88'	23'''-88'''	134'-194'	134'''-194'''	152-208	152''-208''
214'-228	214'''-228''	234-234''	237-237''	269-329	269''-329''	375-433	375''-433''

Glycosylation sites (N)

Asn305 Asn305''

MOLECULAR FORMULA C₆₅₅₂H₁₀₁₃₂N₁₇₅₀O₂₀₂₉S₄₂

MOLECULAR WEIGHT 147.2 kDa

TRADEMARK None as yet

SPONSOR	UCB Biopharma S.P.R.L.
CODE DESIGNATIONS	UCB4940
<u>CAS</u> REGISTRY NUMBER	1418205-77-2
UNII	09495UIM6V
WHO NUMBER	9878

gbk